Overview
Myeloid leukemia encompasses malignancies arising from myeloid progenitor cells, leading to uncontrolled proliferation of immature myeloid cells in the bone marrow and peripheral blood. These conditions vary in severity and prognosis, influenced by factors such as genetic mutations and patient-specific characteristics 1.Diagnosis
Key Diagnostic Criteria: Presence of abnormal myeloid blasts in peripheral blood or bone marrow, often exceeding 20% for acute myeloid leukemia (AML) 2.
Recommended Tests: Bone marrow biopsy and aspiration to assess blast percentage and cytogenetic analysis 2.
Cytochemical and Flow Cytometry: Utilize nonspecific esterase and alkaline phosphatase staining methods for classification 3.
Genetic Analysis: Identify specific mutations that may influence disease progression and therapeutic targets 1.Management
First-Line Treatments:
- Fludarabine and Cytarabine (FLA) ± Gemtuzumab Ozogamicin (GO): For relapsed or refractory myeloid leukemia in children with Down syndrome 2.
- Azacytidine (AZA) ± Panobinostat: Preferred for cases with low blast counts 2.
Adjunctive Treatments:
- Hematopoietic Stem Cell Transplantation (HSCT): Recommended post-remission to improve survival outcomes 2.
- Targeted Therapies: Exploration of BH3 mimetics, LSD1 inhibitors, and JAK inhibitors for future treatment options 2.Special Populations
Pediatrics: Treatment recommendations vary significantly, with specific protocols like FLA ± GO or AZA ± panobinostat tailored for children with Down syndrome 2.
Comorbidities: Management considerations include monitoring for complications such as bone marrow depression, as seen with busulfan treatment 5.Key Recommendations
For relapsed or refractory myeloid leukemia in children with Down syndrome, consider AZA ± panobinostat for low blast counts or FLA ± GO for high blast counts, followed by HSCT post-remission (Evidence: Expert opinion) 2.
Incorporate genetic analysis to identify mutations that may guide targeted therapy approaches (Evidence: Moderate) 1.
Monitor for and manage complications such as bone marrow depression and associated skin conditions like pyoderma gangrenosum, particularly with certain chemotherapeutic agents (Evidence: Weak) 5.References
1 . A Genetic Brake on Blood Cancer Risk. Cancer discovery 2026. link
2 Miladinovic M, Reinhardt D, Hasle H, Goemans BF, Tomizawa D, Hitzler J et al.. Guideline for treating relapsed or refractory myeloid leukemia in children with Down syndrome. Pediatric blood & cancer 2024. link
3 Ross DW, Bishop C, Henderson A, Kaplow L. Whole blood staining in suspension for nonspecific esterase and alkaline phosphatase analyzed with a Technicon H-1. Cytometry 1990. link
4 Burghouts J, Plas AM, Salden M, Wessels J. Improved method of enrichment for immature myeloid cells from normal human bone marrow. Experimental hematology 1980. link
5 Cramers M. Bullous pyoderma gangrenosum in association with myeloid leukaemia. Acta dermato-venereologica 1976. link
6 Tanaka T. Erythropoiesis in murine myeloid leukaemia. British journal of cancer 1970. link